Complete prevention of radiation-induced dermatitis using topical adrenergic vasoconstrictors.
William E Fahl
https://pubmed.ncbi.nlm.nih.gov/27704205/Actively Recruiting
Led by Applied Biology, Inc. · Updated on 2026-08-21
60
Participants Needed
2
Research Sites
4 weeks
Total Duration
Researchers are evaluating DA-020 as a treatment to prevent hair loss caused by chemotherapy, a common and distressing side effect especially for women with breast cancer. This study aims to test whether DA-020, a topical formula containing an 1 agonist, can reduce scalp blood flow and thereby minimize chemotherapy-induced alopecia. The trial is sponsored by Applied Biology, Inc. and focuses on patients with early-stage breast cancer undergoing taxane andor anthracycline chemotherapy. Participants will be randomly assigned to one of three groups topical DA-020 solution, topical placebo solution, or a combination of DA-020 with Hyperforin 1.5%. Each active treatment involves applying 7 mL of the solution to the scalp. The study is designed as a randomized, quadruple-masked trial with parallel groups. The main treatment period lasts 12 weeks, with additional follow-up up to 24 weeks to assess hair regrowth. During the trial, participants will be monitored regularly for hair loss prevention using standardized criteria. Researchers will assess hair loss at baseline and throughout the 12-week treatment and evaluate hair regrowth up to 24 weeks after treatment start. Safety and adherence will be tracked along with any side effects. The total study duration spans from May 2026 to March 2027, including screening, treatment, and follow-up phases.
CONDITIONS
Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia
A
Andy Goren, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Applied Biology, Inc.
Lead Sponsor
Daniel Alain, Inc.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants apply topical DA-020, placebo, or DA-020 with Hyperforin to the scalp as assigned during chemotherapy cycles.
Regular visits during treatment
Duration - Up to 12 weeks post-treatment
Researchers assess hair regrowth and monitor participants for safety after treatment ends.
Periodic follow-up visits
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Have more questions? Get in touch with our team for quick support
William E Fahl
https://pubmed.ncbi.nlm.nih.gov/27704205/Cheryl M Soref, William E Fahl
https://pubmed.ncbi.nlm.nih.gov/24811525/Applied Biology, Inc.
Lead Sponsor
Daniel Alain, Inc.
Collaborating Sponsor